Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gallbladder Neoplasms 2Bile Duct Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Liver Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 23Cisplatin 16pembrolizumab 6Fluorouracil 6pemigatinib 4Radiotherapy 3Oxaliplatin 3Leucovorin 3Drug Therapy 3infigratinib 2durvalumab 2ceritinib 2aldesleukin 2Radiosurgery 2Photochemotherapy 2Nivolumab 2Liver Transplantation 2Dexamethasone 2Cholangiopancreatography, Endoscopic Retrograde 2Carboplatin 2Capecitabine 2trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1spartalizumab 1seribantumab 1perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane) 1peginterferon alfa-2b 1pazopanib 1padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cholangiocarcinoma × becatecarin × Clear all
NCT00090025 2009-01-14

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Helsinn Healthcare SA

Phase 3 Terminated
248 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡